Company news
Medicenna Therapeutics Corp. news in 2018
Medicenna Therapeutics Corp.'s news releases, calls and decks from 2018, newest first.
Medicenna Announces Closing of Previously Announced Public Offering
December 21, 2018
Medicenna Receives US$1.2 Million Non-Dilutive Grant Payment
December 5, 2018
Medicenna Reports Second Quarter Fiscal 2019 Financial Results
November 13, 2018
Medicenna Announces Marketed Offering of Units
November 8, 2018
Medicenna to Present at Upcoming Scientific Conferences
November 7, 2018
Medicenna Provides Positive Interim Update From Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
October 31, 2018
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
October 22, 2018
Medicenna to Present MDNA55 Clinical Results at ESMO Congress
October 16, 2018
Medicenna Solidifies Patent Protection For Long-Acting IL-2 Superkines
September 27, 2018
Medicenna to Present IL-2 Superkine Results at the Sixth Annual Immuno-Oncology Summit
August 28, 2018
Medicenna Reports First Quarter Fiscal 2019 Financial Results
August 13, 2018
Medicenna Provides Development Update on MDNA109 IL-2 Superkine Program
August 2, 2018
Medicenna Strengthens Empowered Cytokine(TM) Platform with Notice of Allowance of US Patent
July 25, 2018
Medicenna Announces March 31, 2018 Year-End Results and Provides Update on Clinical Program
June 27, 2018
Medicenna to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum
May 29, 2018
Medicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response to Strong Safety Data and Early Efficacy Read-outs
May 2, 2018
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
April 25, 2018
Medicenna Reports Third Quarter Fiscal 2018 Financial Results
February 12, 2018